TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable — Class II drug recall D-0730-2022
Terminated recall by Drug Depot, Inc., dba APS Pharmacy, reported 2022-04-06, distributed nationwide. Lack of sterility assurance.
| Recall number | D-0730-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Drug Depot, Inc., dba APS Pharmacy, Palm Harbor, FL, United States |
| Recall initiated | 2022-03-23 |
| Classified | 2022-03-29 |
| Reported by FDA | 2022-04-06 |
| Terminated | 2023-10-05 |
| Distributed | Nationwide (US) |
| Quantity | 846 vials |
| Reason classes | sterility |
| Expiration dates | 2022-06-20, 2022-06-21, 2022-06-27, 2022-08-30 |
Product
TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 4 ML Formula ID 115387; b) (RM) 10 ML Formula ID 115125; APS Pharmacy
Reason for recall
Lack of sterility assurance.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0730-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.